Nintedanib is indicated for the treatment of other progressive, chronic fibrosing interstitial lung diseases (PF-ILD) in adults.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||17/07/2020|
|Rapid review completed||28/08/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nintedanib compared with the current standard of care.|